What Arrowhead Pharmaceutical's Interim Data Reveals About A RNAi Therapeutic For Rare Cholesterol Disorder
Portfolio Pulse from Vandana Singh
Arrowhead Pharmaceuticals presented interim data from its Phase 2 GATEWAY study of ARO-ANG3, an RNAi therapeutic for homozygous familial hypercholesterolemia (HoFH). The company plans to initiate a Phase 3 study and meet with regulatory authorities in 2H 2023.
May 23, 2023 | 5:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arrowhead Pharmaceuticals' ARO-ANG3 shows promising interim data in Phase 2 GATEWAY study for treating HoFH, with plans for a Phase 3 study.
The positive interim data from the Phase 2 GATEWAY study indicates that ARO-ANG3 has potential in treating HoFH. This development is important for Arrowhead Pharmaceuticals as it moves forward with plans for a Phase 3 study and regulatory discussions, which could lead to eventual approval and commercialization of the therapeutic. This news is likely to have a positive short-term impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100